VIS-101, purpose-designed to be best-in-class for retinal vascular diseases, is a tetravalent, dual VEGF-A X ANG-2 ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Gene therapy emerges as a transformative force in ophthalmology, offering renewed hope for patients with retinal diseases. This innovative approach targets both inherited and acquired conditions, ...

FDA authorization under an IND permits first-in-human phase I/II testing of SVT-001 in familial drusen, focusing on safety ...

Neurotech Pharmaceuticals Inc., whose executive chairman is well-known Orange County executive Jim Mazzo, announced that it received FDA approval for its treatment of a type of macular telangiectasia ...

NovaBridge Biosciences NBP shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases. Trial Data The ...

Retinopathy of prematurity (ROP) is one of the most common causes of severe visual impairment and blindness in children worldwide. Because the blood vessels in the retina are not fully developed, ...

Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets - ...

Encinitas, California--(Newsfile Corp. - January 27, 2026) - Kiora Pharmaceuticals (KPRX) has appointed leading retina specialist, Dr. Taiji Sakamoto, an expert in the treatment of retinal disease, to ...

The 2003 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) was held in May in Fort Lauderdale, Florida. The retinal sessions were dominated by reports of new treatments ...

The MarketWatch News Department was not involved in the creation of this content. -- Total potential deal value of $110 million plus royalties -- Kiora to receive an immediate $1.25 million exclusive ...

Joseph Anaya, MD, and Ashkan Abbey, MD, discuss the financial barriers facing patients with geographic atrophy, including ...